People: SciClone Pharmaceuticals Inc (SCLN.O)
SCLN.O on Nasdaq
4.86USD
24 May 2013
4.86USD
24 May 2013
Price Change (% chg)
$-0.11 (-2.21%)
$-0.11 (-2.21%)
Prev Close
$4.97
$4.97
Open
$4.93
$4.93
Day's High
$4.93
$4.93
Day's Low
$4.78
$4.78
Volume
106,161
106,161
Avg. Vol
254,250
254,250
52-wk High
$7.58
$7.58
52-wk Low
$3.68
$3.68
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Jon Saxe |
75 | 2009 | Independent Chairman of the Board |
Friedhelm Blobel |
63 | 2008 | President, Chief Executive Officer, Director |
Gary Titus |
53 | 2008 | Chief Financial Officer, Senior Vice President - Finance |
Hong Zhao |
49 | 2013 | Chief Executive Officer - China Operations |
Simon Li |
2013 | Director | |
Peter Barrett |
60 | 2011 | Independent Director |
Richard Hawkins |
63 | 2004 | Independent Director |
Gregg Lapointe |
53 | 2009 | Independent Director |
Ira Lawrence |
59 | 2006 | Independent Director |
Biographies
| Name | Description |
|---|---|
Jon Saxe |
Mr. Jon S. Saxe, Esquire, J.D., is Independent Chairman of the Board of SciClone Pharmaceuticals, Inc. since July 29, 2009. He has served as a Director since August 2000. Mr. Saxe was President of PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) (NASDAQ: PDLI) from 1995 to early-1999. From 1993 to 1995, Mr. Saxe was President of Saxe Associates, Inc., consultants to venture capital firms and biotechnology, diagnostic, and pharmaceutical companies. He was the President and CEO of Synergen, Inc., a biotechnology company, from 1989 to 1993. Mr. Saxe is former Vice President, Licensing and Corporate Development and Head of Patent Law for Hoffmann-LaRoche Inc., where he worked for 30 years. Mr. Saxe received his J.D. from George Washington University School of Law and his LL.M. from New York University School of Law. He serves as a director of other public and private companies, including Durect Corporation (NASDAQ: DRRX). |
Friedhelm Blobel |
Dr. Friedhelm Blobel, Ph.D. is President, Chief Executive Officer and Director of SciClone Pharmaceuticals, Inc. From July 2000 to 2006, Dr. Blobel was President, CEO and a Director of Gryphon Therapeutics, Inc., a South San Francisco based biopharmaceutical company. Prior to joining Gryphon Therapeutics in July 2000, Dr. Blobel spent two decades as an executive with the Hoechst Group and the Boehringer Mannheim Group including responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer and General Manager in Tokyo, Japan of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas Pharma, Inc.), Senior Vice President of Research and Development Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, Indiana. Dr. Blobel earned his doctorate degree with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany. |
Gary Titus |
Mr. Gary S. Titus is Chief Financial Officer, Senior Vice President - Finance of SciClone Pharmaceuticals, Inc., since December 2008. Prior to joining SciClone, Mr. Titus served as Senior Vice President of Finance and Chief Financial Officer at Kosan Biosciences, Incorporated, which was acquired by Bristol-Myers Squibb Company in June 2008, from September 2006 until September 2008. From 2003 to 2006, Mr. Titus was with Nuvelo, Inc. and served as Chief Financial Officer and Vice President from October 2005 to September 2006. Mr. Titus has also held positions at life sciences companies including Metabolex, Inc., Intrabiotics Pharmaceuticals, Inc., and LifeScan, Inc., a division of Johnson & Johnson. Mr. Titus holds a Bachelors of Science degree in Accounting from the University of South Florida and a Bachelor of Science degree in Finance from University of Florida and is a Certified Public Accountant. |
Hong Zhao |
Mr. Hong Zhao has been appointed as Chief Executive Officer - China Operations of Sciclone Pharmaceuticals Inc., effective April 1, 2013. Prior to joining SciClone, Mr. Zhao served as Executive Vice President at Simcere Pharmaceuticals Group, Inc. since 2011 and served in various positions at Novartis, including most recently as Senior Vice President of Novartis Greater China and General Manager of Novartis Shanghai, from 1999 to 2011. Prior to Simcere, he held positions of increasing seniority at Novartis China, from Regional Sales Manager, National Sales Director, Vice President, Senior Vice President of Novartis Greater China and General Manager of Novartis Shanghai. Mr. Zhao also served with Xi’an Janssen Pharmaceutical, where he rose quickly from Medical Representative to District Sales Prior to Simcere, he held positions of increasing seniority at Novartis China, from Regional Sales Manager, National Sales Manager. Earlier in his career he served as a lecturer and tutor at Nanjing Medical College. Mr. Zhao earned a Bachelor of Medicine degree from Nanjing Medical College and an Executive Masters of Business Administration degree from China European International Business School (CEIBS) in Shanghai. |
Simon Li |
Mr. Simon Li is appointed as the Director of SciClone Pharmaceuticals, Inc. Most recently, Mr. Li served as the Global Officer and Member of the Executive Committee of Medtronic, a global medical technology company, and also held the positions of President, Greater China and Chairman of the Board, Medtronic-Weigao JV. Prior to Medtronic, Mr. Li was the International Vice President, North Asia / New Business Development, Asia Pacific / Strategic Medical Affairs, Asia Pacific with Johnson & Johnson Medical, China. Earlier in his career with J&J, he held the positions of International Vice President, North Asia, Managing Director, China and Hong Kong, and Managing Director, China. Prior to J&J, Mr. Li was President and Chief Operating Officer of the ConvaTec business with Bristol-Myers Squibb in Hong Kong. He also served as General Manager of the pharmaceutical distributor Y.C. Woo & Co., Ltd. in Hong Kong. Mr. Li’s current non-executive activities include serving on the board of directors of Shandong Weigao Group Medical Polymer, and he has received several industry honors. He earned a Bachelor of Arts degree in social sciences from the University of Hong Kong, an M.B.A. degree from Henley Management, and an advanced E.M.B.A. from Harvard Business School. |
Peter Barrett |
Mr. Peter Barrett is Independent Director of SciClone Pharmaceuticals Inc. He has been a Partner in the Life Sciences group at Atlas Venture since 2002. Prior to joining Atlas, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics. Prior to Celera, he held senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development. He serves as a director of other public and private companies, including Helicos Biosciences Corporation (HLCS), and was a member of the Board of Directors of NovaMed Pharmaceuticals, Inc. (“NovaMed”) prior to its acquisition by SciClone. Mr. Barrett is currently Vice Chairman of the Advisory Council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University, as well as Adjunct Professor at the Barnett Institute. He also serves as President of the Autism Consortium, a non-profit institution. Mr. Barrett received his Ph.D. in Analytical Chemistry from Northeastern University. |
Richard Hawkins |
Mr. Richard J. Hawkins is Independent Director of SciClone Pharmaceuticals, Inc. since October 2004. Mr. Hawkins served as the Chairman and CEO of LabNow, Inc., a privately-held company he founded in September 2003 that develops lab-on-a-chip sensor technology to be used in point-of-care diagnostic testing systems. From 1994 to 2000, Mr. Hawkins co-founded Corning BioPro, a protein contract manufacturing firm. From 1992 to 2000, Mr. Hawkins co-founded and served as Chairman of Sensus Drug Development, which developed and received regulatory approval for SOMAVERT, a growth hormone antagonist approved for the treatment of acromegaly and now marketed by Pfizer in both the United States and Europe. In 1982, Mr. Hawkins founded Pharmaco, a clinical research organization (CRO) that in 1991 was merged with the predecessor of PPD-Pharmaco, one of the CROs in the world today. Mr. Hawkins graduated cum laude with a B.S. in Biology from Ohio University. |
Gregg Lapointe |
Mr. Gregg Anthony Lapointe CPA, is Independent Director of SciClone Pharmaceuticals, Inc. since March 2009. Mr. Lapointe has served as Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc., the U.S. wholly-owned subsidiary of Sigma-Tau Finanziaria S.pA., since April 2008. He served as Chief Operating Officer of Sigma-Tau Pharmaceuticals, Inc. from November 2003 to March 2008. Mr. Lapointe is a Certified Public Accountant in the United States and a Chartered Accountant in Canada. He holds a Bachelor of Commerce degree from Concordia University of Montreal, a Graduate Diploma in Public Accountancy from McGill University of Montreal and an M.B.A. from Duke University. Mr. Lapointe has experience in finance and management, including operational experience as the CEO of a pharmaceutical development and sales organization. |
Ira Lawrence |
Dr. Ira D. Lawrence, M.D., is Independent Director of SciClone Pharmaceuticals, Inc. since June 2005. Dr. Lawrence is Chief Medical Officer and Senior Vice President of Research and Development at Medicis Pharmaceutical Corporation (NYSE: MRX). From June 2005 until May 2006, Dr. Lawrence served as President and Chief Executive Officer. From 1995 to 2005, Dr. Lawrence was employed with Fujisawa Healthcare, Inc. (merged with Yamanouchi Pharmaceutical Co. to form Astellas Pharma, Inc.), as Senior Vice President of Research and Development. From 1993 to 1995, Dr. Lawrence served as Vice President of Research and Development at GenDerm Corporation. Dr. Lawrence was the Associate Director of Clinical Studies, Immunology at Fujisawa Healthcare, Inc. from 1991 to 1993. Prior to 1991, Dr. Lawrence practiced internal medicine and allergy/clinical immunology,as the Assistant Chief of Staff at the Veterans Administration Lakeside Medical Center and Assistant Professor at Northwestern University Medical School. Dr. Lawrence earned his M.D. degree, from the Hahnemann Medical College (now Drexel University College of Medicine) and his B.A. from Temple University. Dr. Lawrence completed his internship and residency in internal medicine at Northwestern University and his fellowship at the Division of Allergy and Clinical Immunology at the Johns Hopkins University School of Medicine. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Jon Saxe |
-- |
Friedhelm Blobel |
1,635,620 |
Gary Titus |
1,357,050 |
Hong Zhao |
-- |
Simon Li |
-- |
Peter Barrett |
-- |
Richard Hawkins |
-- |
Gregg Lapointe |
-- |
Ira Lawrence |
443,782 |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Jon Saxe |
0 | 0 |
Friedhelm Blobel |
0 | 0 |
Gary Titus |
0 | 0 |
Hong Zhao |
0 | 0 |
Simon Li |
0 | 0 |
Peter Barrett |
0 | 0 |
Richard Hawkins |
0 | 0 |
Gregg Lapointe |
0 | 0 |
Ira Lawrence |
800,000 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
BLOBEL FRIEDHELM |
1,000 | $3.68 |
BLOBEL FRIEDHELM |
1,000 | $3.72 |
BLOBEL FRIEDHELM |
1,000 | $4.17 |
TITUS GARY S |
36,954 | $0.95 |
TITUS GARY S |
29,624 | $0.95 |
TITUS GARY S |
36,954 | $6.99 |
TITUS GARY S |
29,624 | $6.99 |
BLOBEL FRIEDHELM |
100,000 | $1.08 |
BLOBEL FRIEDHELM |
11,000 | $7.29 |
TITUS GARY S |
15,029 | $7.05 |
BLOBEL FRIEDHELM |
100,000 | $7.01 |
TITUS GARY S |
15,029 | $0.95 |
BLOBEL FRIEDHELM |
1,000 | $3.84 |
TITUS GARY S |
261 | $3.84 |
TITUS GARY S |
9,357 | $0.00 |
BLOBEL FRIEDHELM |
7,018 | $0.00 |
SAXE JON S |
20,000 | $3.84 |
SIGMA TAU FINANZIARIA S P A |
6,328,469 | $5.25 |
CAVAZZA PAOLO |
252,469 | $5.25 |
CAVAZZA PAOLO |
147,531 | $5.25 |
CAVAZZA PAOLO |
252,469 | $5.25 |
CAVAZZA PAOLO |
6,328,469 | $5.25 |
SIGMA TAU FINANZIARIA S P A |
252,469 | $5.25 |
RIOS ISRAEL |
48,750 | $1.08 |
TITUS GARY S |
241 | $3.78 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
